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Abstract
Background: Chronic hepatitis B (CHB) virus infection is a major cause of hepatocellular carcinoma (HCC), as late
diagnosis is the main factor for the poor survival of patients. There is an urgent need for accurate biomarkers for
early diagnosis of HCC. The aim of the study was to explore the serum lipidome profiles of hepatitis B-related HCC
to identify potential diagnostic biomarkers.
Methods: An ultraperformance liquid chromatography mass spectrometry (UPLC-MS) lipidomic method was used
to characterize serum profiles from HCC (n = 32), liver cirrhosis (LC) (n = 30), CHB (n = 25), and healthy subjects (n = 34).
Patients were diagnosed by clinical laboratory and imaging evidence and all presented with CHB while healthy
controls had normal liver function and no infectious diseases.
Results: The UPLC-MS-based serum lipidomic profile provided more accurate diagnosis for LC patients than
conventional alpha-fetoprotein (AFP) detection. HCC patients were discriminated from LC with 78 % sensitivity
and 64 % specificity. In comparison, AFP showed sensitivity and specificity of 38 % and 93 %, respectively. HCC
was differentiated from CHB with 100 % sensitivity and specificity using the UPLC-MS approach. Identified lipids
comprised glycerophosphocolines, glycerophosphoserines and glycerophosphoinositols.
Conclusions: UPLC-MS lipid profiling proved to be an efficient and convenient tool for diagnosis and screening
of HCC in a high-risk population.
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Background
Hepatitis B virus (HBV) infection is one of the main
causes of chronic liver disease worldwide. It is estimated
that 240 million individuals are chronically infected with
HBV [1]. Depending on the presence of co-factors, pro-
gression to liver cirrhosis (LC) may occur at a rate of 2 to
10 % per year, whereas hepatocellular carcinoma (HCC)
may develop in 2–4 % of patients per year. HBV is esti-
mated to be responsible for 30 % of cirrhosis- and 45 % of
HCC-related deaths [2].
In Brazil, HBV accounts for 13–25 % of HCC cases in
most geographical regions, reaching 40 % of HCC cases
in the Mid-west [3].
HCC is a complex and heterogeneous tumor with
several genomic alterations and its incidence has been
increasing worldwide. It is the sixth most common can-
cer and the second cause of cancer-related death. When
diagnosed at an early stage, surgical options such as
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resection or liver transplantation, or local ablative therap-
ies, can be applied with intent to cure HCC. However, until
now, no effective serum or plasma biomarkers have been
found for accurate screening or diagnosis of HCC [4, 5].
HCC diagnosis is most commonly performed by ultra-
sound examination, CT scan and/or magnetic resonance.
Histopathology confirmation may also be necessary in
some cases. However, there are some limitations related
to risk of complications and feasibility of the biopsy due
to tumor location. Moreover, the effectiveness of ultra-
sound for early detection of HCC is highly dependent on
the stage of liver fibrosis, the quality of the equipment
and the expertise of the operator [4].
Alpha-fetoprotein (AFP) is the most widely used bio-
marker for HCC. However, its sensitivity is only up to
60 % and elevated AFP levels are also common in LC
and chronic liver disease [6]. Thus, there is an urgent
need to identify better HCC biomarkers.
The ideal biomarker should be specific and able to dis-
criminate HCC from regenerative nodules irrespective of
the stage of liver disease. Furthermore, the biomarker
should be sensitive, allowing detection at an early stage,
and should be easily measurable, reproducible, and min-
imally invasive.
Recently developed mass spectrometry (MS)-based
techniques such as lipidomics are promising tools for
the discovery and subsequent identification of mole-
cules associated with various diseases. Separation tech-
niques, like ultraperformance liquid chromatography
(UPLC), coupled to MS enable the analysis of complex
samples such as plasma or serum with very high sensi-
tivity and accuracy [7, 8].
Once lipid biomarkers are identified through UPLC-
MS, they can be later investigated in clinical laboratory
routine using simple and accessible colorimetric and/or
enzymatic techniques. Nonetheless, studies on lipid pro-
filing and fingerprinting of HCC are still scarce [9–12].
The aim of this study was to assess the serum lipid
patterns of HCC by performing UPLC-MS to search for
potential biomarkers for diagnosis in HBV chronic in-
fected patients (HBV-HCC).
Methods
Study design, sample and data collection
A total of 87 patients with chronic hepatitis B (CHB) were
enrolled from 2012 to 2014 at the Hospital das Clínicas of
the University of Sao Paulo School of Medicine, including
32 patients with HBV-HCC, 30 patients with HBV-LC
and 25 patients with CHB. Additionally, 34 eligible blood
donors with normal liver function and no infectious dis-
eases were recruited at COLSAN Beneficent Association
for Blood Collection to serve as healthy controls. CHB
was diagnosed based on the presence of HBsAg for at
least 6 months. LC was diagnosed by histopathology,
clinical features and/or elastography and HCC was di-
agnosed using imaging or histopathology techniques, in
accordance with guidelines of the Brazilian Society of
Hepatology.
Blood samples were obtained by venipuncture and
drained into blood collection tubes. The samples were
centrifuged immediately after collection and serum was
stored at −80 °C until analysis.
Demographic, clinical and laboratory data were col-
lected from medical records. The study was approved by
the ethics committee of human research of the Federal
University of Sao Paulo and the University of São Paulo
School of Medicine (2012/81656 and 2014/569922) and
all patients gave written informed consent.
Extraction of lipids
Lipids were extracted from each sample using a modified
Bligh-Dyer protocol [13]. Immediately after thawing,
100 μL of serum were dissolved in 850 μL of a mixture of
water/chloroform/methanol (1:2.5:5, v/v) and vortexed
well for 5 min. After vortexing, 250 μL of chloroform
were added and the tubes were agitated for 15 min at
700 rpm. Then, 200 μL of deionized water were added
and the tubes were centrifuged at 14,000 rpm for 15 min
at room temperature. Following this protocol a 2-phase
system (aqueous top, organic bottom) was achieved. The
bottom phase containing lipids was gently recovered using
a micropipette, dried, and resuspended in 350 μL of aceto-
nitrile/water (3:2, v/v). All chemicals were of analytical re-
agent grade and used as received.
UPLC-MS analysis
Reversed-phased analysis was performed on a Waters
ACQUITY IClass UPLC system equipped with a Wa-
ters Acquity CSH C18 1.7 μm x 2.1 × 100 mm column
coupled to a Waters Synapt-MS hidrid quadrupole-
time of flight mass spectrometer operating in the posi-
tive ion electrospray mode. A mass scan range of 200
to 1,200 mass-to-charge ratio (m/z) was set for data ac-
quisition in continuous mode with optimized parame-
ters for ionization and mass transmission. Acetonitrile/
water (3:2, v/v) was used as mobile phase A and isopropa-
nol/acetonitrile (9:1, v/v) was used as mobile phase B, both
with 10 mM ammonium formate and 0.1 % formic acid as
additives. The flow rate was set at 600 μL/min and the in-
jection volume was 10 μL. A binary gradient was opti-
mized as follows: the composition of mobile phase B was
changed from 15 % to 30 % in 2 min, then to 48 % in 30 s
and reached 82 % in 8.5 min. Subsequently, it was changed
to 99 % in 30 s, held for another 30 s and then dropped to
15 % in 6 s prior to being held until a total run time of
15 min. The mass spectrometer was previously calibrated
with 0.1 % phosphoric acid in water/acetonitrile (1:1, v/v)
and a solution of 0.5 ng/μL leucine enkephalin in water/
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acetonitrile (1:1, v/v) with 0.1 % formic acid infused in the
reference probe at a flow rate of 5 μL/min was used as
lock mass spray at a 30 s frequency for accurate mass
determination. All analyses were acquired using the
lock spray and the instrument was recalibrated every 4
run-hours to ensure accuracy and reproducibility. Fur-
thermore, a quality control of pool plasma samples was
analyzed after every 10 runs, and 10 peaks well distrib-
uted from 200 to 1,200m/z were assessed.
Data pretreatment and statistical data analyses
All data obtained from the UPLC-MS analyses were proc-
essed with the Waters Progenesis software (Manchester,
UK). This step included mass correction, chromatograms
and spectra alignment and peak detection using default
parameters. After attribution, the matrix of the features
characterized by their m/z and retention time (RT) was
uploaded into the MetaboAnalyst 3.0 (The Metabolomics
Innovation Centre, Canada). For normalization, data was
mean-centered and divided by the square root of standard
deviation of each variable (Pareto scaling).
For multivariate analysis, the unsupervised principal
component analysis (PCA) was first utilized in all sam-
ples (Additional file 1). Supervised partial least-squares-
latent structure discriminate analysis (PLS-DA) was then
performed to identify biomarkers that contributed to the
clustering. Validation with a permutation test and 100
repetitions was performed to prevent model overfitting.
Potential biomarkers that differentiated HCC from LC,
CH and healthy subjects (HS) were selected based on
the variable importance in the projection (VIP) values
and univariate statistical significance after Mann–Whit-
ney test and fold-change analyses. Receiver operating
characteristic (ROC) curves were performed to evaluate
the accuracy of the potential biomarkers and the pro-
posed model using the ROCCET (The Metabolomics
Innovation Centre, Canada).
Statistical analyses of demographic, clinical and la-
boratory data of subjects were performed using SPSS
version 11.0 (SPSS Inc., Chicago, IL, USA). Descriptive
statistics consisted of the characterization of the stud-
ied population (demographic, clinical and laboratory
characteristics) through the respective percentages or
mean/median and standard deviation (SD) for continuous
variables. Bivariate analysis consisted of Fisher exact test
to compare categorical values. For continuous variables,
Student’s t-test was use to compare means of normally
distributed variables, while non-normally distributed vari-
ables were subjected to Mann–Whitney U test. Statistical
significance level was P < 0.050. All reported values are 2-
tailed.
A tentative identification of the differentiating lipids was
performed on the LIPID MAPS and HMDB databases.
Results
The mean age of patients was 59.0 years old in the HCC
group, 56.8 in the LC group, and 37.1 in the CHB group.
The mean age of the HS was 42.6 years. In the HCC
group 81.3 % of patients were males, while in the LC,
Table 1 Demographic data of the enrolled population of the
study by group
Characteristics HS CH LC HCC P
Number 34 25 30 32 -
Mean age ± SD 42.6 ± 14.8 37.1 ± 14.2 56.8 ± 11.0 59.0 ± 11.3 0.447
Median age 42.0 35.0 56.5 57.0 0.812
Age range 21–67 19–63 34–80 38–85 -
Gender (M/F) 13/21 17/8 20/10 26/6 0.190
HS healthy subjects, CH chronic hepatitis, LC liver cirrhosis, HCC hepatocellular
carcinoma, SD standard deviation, M male, F female
Table 2 Clinical and laboratory data of patients with liver
cirrhosis and hepatocellular carcinoma
Characteristics LC HCC P
AFP (ng/mL) 6.2 ± 15.8 507.8 ± 1565.9 < 0.001*
AFP≥ 20 ng/mL 2 (6.67) 12 (37.5) -
AFP≥ 200 ng/mL 0 (0.0) 6 (18.8) -
ALT (UI/mL) 35.4 ± 41.3 39.5 ± 43.2 0.698
AST (UI/mL) 37.3 ± 22.4 45.3 ± 43.0 0.746
ALP (U/L) 86.6 ± 51.6 119.2 ± 70.1 0.022*
GGT (U/L) 64.2 ± 98.2 108.1 ± 121.0 0.045*
Total bilirubin (mg/dL) 0.7 ± 0.3 1.1 ± 1.4 0.481
Albumin (g/dL) 4.7 ± 0.4 4.4 ± 0.8 0.117
Platelets (*1,000/mm3) 155.8 ± 89.5 156.0 ± 86.3 0.910
PT (seconds) 14.1 ± 2.1 13.2 ± 1.7 0.013*
Child-Pugh score
A 30 (53.6) 26 (46.4) 0.030*
B or C 0 (0.0) 6 (100.0)
Total cholesterol (mg/dL) 179.4 ± 38.1 172.8 ± 41.0 0.511
Tumor size (mm) - 37.0 ± 23.0 -
BCLC stage
0 - 5 (15.6) -
A - 14 (43.8) -
B - 10 (31.2) -
C - 1 (3.1) -
D - 2 (6.3) -
Results are presented as number and percentage for categorical variables and
as mean value and standard deviation for continuous variables. LC liver
cirrhosis, HCC hepatocellular carcinoma, AFP alpha-fetoprotein, ALT alanine
aminotransferase, AST aspartate aminotransferase, ALP alkaline phosphatase,
GGT gamma glutamyl transpeptidase, PT prothrombin time, BCLC Barcelona-
Clinic Liver Cancer. *Significant at 0.05
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CH and HS groups they were 66.7, 68.0 and 38.2 %, re-
spectively (Table 1).
Clinical and laboratory data analyses were performed
for the HCC and LC groups (Table 2). In summary, the
mean levels of AFP, alkaline phosphatase (ALP), and
gamma-glutamyl transpeptidase (GGT) were signifi-
cantly higher in the HCC group, while prothrombin time
(PT) was lower. Nonetheless, the Child-Pugh score dis-
tribution was only slightly different between the LC and
the HCC groups, which presented 4 and 2 patients with
B and C scores, respectively. Twenty-eight of the 32 HCC
patients (87.5 %) presented with LC. HCC was classified
as BCLC—Barcelona Clínic Liver Cancer staging system
very early or early stage in 19 of the 32 cases (59.4 %),
intermediate stage in 10 (31.2 %) and advanced or ter-
minal stage in only 3 (9.4 %) cases (Additional file 2.).
A total of 2,698 ions were detected using the UPLC-
MS method in this study. Figure 1 shows the PLS-DA
score plot for the 4 groups evaluated. The separate
PLS-DA score plots for inter-group comparisons are
shown in Fig. 2.
Hepatocellular carcinoma versus liver cirrhosis
Four lipids independently predicted HCC from LC with
65.6–84.4 % sensitivity, and 60.0–76.7 % specificity.
Figure 3 shows the intensities and ROC curves of the 4
lipids in patients with HCC and LC.
Based on the efficiency of the ROC curves, cutoff
values were determined for each ion. The number of
“positive” ions in each sample was used to generate a 4-
peak algorithm with cutoff value of at least 2 “positive”
biomarkers, defined by ROC curve analysis and posterior
univariate statistical validation (Fig. 4a). The 4-peak al-
gorithm generated distinguished HCC from LC with an
accuracy of 71.0 % (95 % CI 58.7–80.1 %), a sensitivity of
78.1 % (95 % CI 61.2–89.0 %), and a specificity of 63.6 %
(95 % CI: 45.4–78.1 %). This algorithm successfully de-
tected 25 of 32 HCC cases when applied to discriminate
HCC from LC.
Conversely, AFP detected only 12 of 32 HCC cases
from LC when cutoff value was set as 20 ng/mL, show-
ing an accuracy of 64.5 % (95 % CI 52.1–75.3 %), a sensi-
tivity of 37.5 % (95 % CI 22.9–54.8 %), and a specificity
of 93.3 % (95 % CI: 78.7–98.2 %). In the range of
200 ng/mL, AFP detected 6 of 32 HCC cases, perform-
ing with an accuracy of 58.1 % (95 % CI 45.7–69.5 %), a
sensitivity of 18.8 % (95 % CI: 8.9–35.3 %), and a specifi-
city of 100 % (95 % CI 88.7–100.0 %) (Table 3).
The accuracy, sensitivity and specificity of HCC de-
tection of the 4-peak algorithm was not compromised
when the 6 HCC patients with Child-Pugh scores B and
C were excluded from the analysis. Likewise, the HCC
detection rate of the algorithm did not vary significantly
when patients were stratified according to the BCLC
Fig. 1 PLS-DA scores plot based on the UPLC-MS profiling data for the studied groups. Detailed legend: The score plots show the first, second
and third latent variables. Each dot in the plot represents a patient according to its group. HCC, hepatocellular carcinoma; LC, liver cirrhosis; CH,
chronic hepatitis; HS, healthy subjects
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staging system (P = 0.463). Very early or early HCC was
detected with a sensitivity of 73.7 % (95 % CI: 51.2–
88.2 %), and a specificity of 63.3 % (95 % CI: 45.5–78.1 %).
The combination of the 4-peak UPLC-MS algorithm with
AFP in the range of 20 ng/mL was able to distinguish HCC
from LC with an accuracy of 79.0 % (95 % CI 67.4–87.3 %),
a sensitivity of 75 % (95 % CI 57.9–86.8 %), and a specificity
of 83.3 % (95 % CI: 66.4–92.7 %).
Hepatocellular carcinoma versus chronic hepatitis B
The 4 peaks independently predicted HCC from CHB
with 52–90.6 % sensitivity and 68.8–86.7 % specificity.
The intensities and ROC curves of the 4 lipids in patients
with HCC and CHB are shown in Additional file 3. The
4-peak algorithm distinguished HCC from CHB with
an accuracy of 87.1 % (95 % CI 76.6–93.3 %), a sensitiv-
ity of 93.8 % (95 % CI 79.9–98.3 %), and a specificity of
80.0 % (95 % CI 62.7–90.5 %) (Table 3).
As the ion RT 4.26_540.4255m/z did not perform well
in this comparison, we also tested the performance of the
model using different combinations of the 4 ions. The best
model was a combination of the ion RT 1.30_498.8315m/z
and RT 1.32_497.5731m/z, which with a cutoff of at
least 1 “positive” ion, detected 31 of the 32 HCC cases
and distinguished HCC and CHB with an accuracy of
88.7 % (95 % CI 78.5–94.4 %), a sensitivity of 96.9 %
(95 % CI 84.26–99.5 %), and a specificity of 80.0 %
(95 % CI 62.7–90.5 %) (Fig. 4b).
Fig. 2 PLS-DA scores plot based on the UPLC-MS profiling data for (a) HCC versus HS; (b) HCC versus CH; (c) HCC versus LC; (d) LC versus CH versus
HS. Detailed legend: The score plots show the first, second and third latent variables for each plot. Each dot in the plot represents a patient according
to its group. HCC, hepatocellular carcinoma; LC, liver cirrhosis; CH, chronic hepatitis; HS, healthy subjects
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We also looked at the whole lipidomic profile of HCC
and CHB and, interestingly, 7 peaks independently pre-
dicted HCC from CHB with 100 % sensitivity and specifi-
city (Additional file 4).
Tentative identification of potential biomarkers
Table 4 shows the main classes and subclasses associ-
ated with the differentiating lipids found in this study.
Discussion
Diagnosis of HCC at an early stage is essential for dis-
ease prognosis as it allows the application of curative
treatments and improves patient survival.
In the present study, an UPLC-MS-based lipidomic ex-
pression signature successfully distinguished HBV-HCC
cases from HBV-LC with 78.1 % sensitivity and 63.6 %
specificity and provided a more precise diagnostic instru-
ment for cirrhotic patients than conventional non-invasive
Fig. 3 ROC curves and intensities of the differential ions in the UPLC-MS 4-peak model by RT and m/z. Detailed legend: ROC curves and intensities of
the differential ions in the ULC-MS 4-peak model in HCC (red boxes) and LC (green boxes) patients for the ions (a) RT 1.30_498.8315m/z; (b)
RT 1.32_497.5731m/z; (c) RT 1.30_496.6721m/z; (d) RT 4.26_540.4255m/z. AUC, area under the curve; HCC, hepatocellular carcinoma; LC, liver
cirrhosis; CH, chronic hepatitis; HS, healthy subjects
Fig. 4 ROC curves of the UPLC-MS 4-peak algorithm in differentiating (A) HCC from LC and (B) HCC from CH. Detailed legend: AUC, area under
the curve; HCC, hepatocellular carcinoma; LC, liver cirrhosis; CH, chronic hepatitis; HS, healthy subjects
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biomarker detection (AFP). Our results also show that the
UPLC-MS lipidomic fingerprinting discriminated serum
lipidomic expression patterns among patients with HBV-
HCC, HBV-LC, and CHB.
Studies on lipidomic profiling of HCC are still scarce.
Moreover, key data are lacking in the few published
studies, such as comprehensive description and assess-
ment regarding patient and background liver disease
characterization, group allocation and controls adequacy,
and proper performance assessment of the diagnostic
model, among others [14].
The results presented herein are innovative, as this
study performs a robust evaluation of patients enrolled
in a well-established HCC surveillance program. These
patients are, therefore, well characterized as to their
clinical and laboratory parameters, which ensures the
adequacy of the study groups and controls, and allows
an unbiased interpretation of the proposed biomarkers
and their intra-group level variations.
When used as a diagnostic biomarker, AFP is expected
to misdiagnose up to 40 % of HCC cases with a 20 ng/mL
cutoff value [4]. In this study, however, while the UPLC-
MS-based 4-peak model accurately diagnosed 25 of 32
HCC cases from LC patients, AFP performed poorly, de-
tecting only 12 of 32 cases with a sensitivity of 37.5 % and
93.3 % specificity.
When applied to differentiate HCC in the early stages,
the UPLC-MS signature detected very early or early stage
HCC with 73.7 % sensitivity and 63.3 % specificity. These
data show the potential applicability of UPLC-MS for
screening biomarkers for early diagnosis of HCC.
Patients at high risk of HCC development should be
screened semi annually using ultrasonography (US). It is
known, however, that in most cases US has only accept-
able diagnosis accuracy with sensitivity ranging from 58
to 89 % and specificity greater than 90 % [4, 15, 16]. Fur-
thermore, US effectiveness for detecting early-stage HCC
is even lower, with a sensitivity of only 63 % [17]. The ac-
curacy of the proposed UPLC-MS 4-peak model for HCC
screening and the actual gain in the detection rate need
to be further evaluated on larger studies. Nonetheless,
the use of this model might improve HCC surveillance
and diagnosis, especially in resource-limited regions
where patients may have difficult access to US and higher
resolution imaging techniques such as CT scan and mag-
netic resonance. A lipidomic biomarker and/or profile
could be, in turn, detected through a simple, inexpensive
and widely accessible enzyme immunoassay or chemilu-
minescence assay, which would represent a significant re-
duction on HCC screening costs.
HBV infection can lead to HCC in the absence of cir-
rhosis. Although little is known about the clinical and
epidemiological aspects of HCC in Brazil [18], data from
other regions show that 20 to 30 % of patients with
Table 3 Sensitivity and specificity of UPLC-MS profiles, AFP and
individual peaks for HCC diagnosis
Test Sensitivity (%) Specificity (%) ROC AUC
HCC versus LC
4-ion UPLC-MS model 78.1 63.6 0.819b,c
AFP20 ng/mL 37.5 93.3 0.779
d
AFP200 ng/mL 18.8 100.0 0.779
d
4-ion UPLC-MS model 75.0 83.3 0.856
+ AFP20 ng/mL
a
HCC versus CHB
4-ion UPLC-MS model 93.8 80.0 0.864e,f
2-ion UPLC-MS model 96.9 80.0 0.933g
RT 3.40_773.5478 n 100.0 100.0 1.000
RT 1.87_534.3902m/z 100.0 100.0 1.000
RT 6.25_369.3538m/z 100.0 100.0 1.000
RT 3.45_822.5670m/z 100.0 100.0 1.000
RT 3.59_770.5691m/z 100.0 100.0 1.000
RT 4.23_851.6090m/z 100.0 100.0 1.000
RT 3.99_826.5920m/z 100.0 100.0 1.000
HCC versus HS
4-ion UPLC-MS model 90.6 88.2 0.946
ROC receiver operating characteristic, AUC area under the curve, HCC
hepatocellular carcinoma, LC liver cirrhosis, AFP alpha-fetoprotein, UPLC
ultra performance liquid chromatography, MS mass spectrometry, CHB
chronic hepatitis B, RT retention time, n neutral, m/z mass to charge ratio,
HS healthy subjects.
aCombination of the 4-ion UPLC-MS model and AFP20 ng/mL.
bCompared with AFP20 ng/mL or AFP200 ng/mL, P = 0.616.
cCompared with 4-ion UPLC-MS model + AFP20 ng/mL, P = 0.610.
dCompared with 4-ion UPLC-MS model + AFP20 ng/mL, P = 0.312.
eCompared with 2-ion UPLC-MS model, P = 0.241.
fCompared with individual ions, P = 0.047.
gCompared with individual ions, P = 0.005
Table 4 Tentative identification of potential UPLC-MS biomarkers
for HCC
RT_m/z Adduct Identified result Main class
1.30_498.8315 [M + H]+ unknown -
1.32_497.5731 [M + H]+ unknown -
1.30_496.6721 [M + H]+ unknown -
4.26_540.4255 [M + H]+ unknown -
3.40_773.5478 [M + H]+ PS(O-16:0/20:2)a Glycerophosphoserines
1.87_534.3902 [M + H]+ unknown -
6.25_369.3538 [M + H]+ unknown -
3.45_822.5670 [M + H]+ PS(O-18:0/22:6)b Glycerophosphoserines
3.59_770.5691 [M + H]+ PC(15:0/20:3)c Glycerophosphocholines
4.23_851.6090 [M + H]+ PI(O-16:0/20:1)d Glycerophosphoinositols
3.99_826.5920 [M + H]+ PS(O-18:0/22:4)e Glycerophosphoserines
a(11Z,14Z); b(4Z,7Z,10Z,13Z,16Z,19Z); c(8Z,11Z,14Z); d(11Z); e(7Z,10Z,13Z,16Z)/
22:5(4Z,7Z,10Z,13Z,16Z). TG, triacylglycerol; PS, phosphatidylserine; PC,
phosphatidylcholine; PI, phosphatidylinositol; m/z, mass to charge ratio
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HBV-related HCC do not present with LC [19]. In this
study the rate of HCC in the absence of cirrhosis was
12.5 %. The UPLC-MS 4-peak detected HCC from CHB
patients with of 93.8 % sensitivity and a specificity of
80.0 %. Furthermore, it was observed that some peaks not
included in the first model could differentiate HCC and
CHB with 100 % sensitivity and specificity.
We performed a tentative and preliminary identifica-
tion of the differentially expressed peaks. At this point
we have identified 3 glycerophosphoserines, 1 glycero-
phosphocholine and 1 glycerophosphoinositol, all in
significantly lower levels in HCC patients.
Previous studies also have shown lower levels of glycero-
phosphocolines in HCC patients, which are the most
abundant phospholipid in mammalian cellular membranes
[11]. This under expression may result from the inflam-
matory response and consequent higher consumption of
these lipids [20, 21]. CHB infection has been associated
with alterations in lipid metabolism and a recent study
showed that HBV infection altered the metabolic gene ex-
pression in a human liver-chimeric mouse model by alter-
ing bile acid and cholesterol metabolism as a consequence
of impaired bile acid uptake [22].
Conclusions
Our findings suggest that UPLC-MS lipidomic finger-
printing may be a powerful tool for the identification of
diagnostic biomarkers and models for hepatitis B virus-
related HCC. These data showed that the lipid finger-
printing in HCC patients selected a number of lipids
that should be functionally investigated to elucidate the
pathogenesis of the disease. This technique and the se-
lected peaks show a great potential to improve HCC
surveillance in patients with LC and CHB.
Additional files
Additional file 1: PCA scores plot based on the UPLC-MS profiling
data for the studied groups. The score plots show the first, second and
third principal components. Each dot in the plot represents a patient
according to its group. HCC, hepatocellular carcinoma; LC, liver cirrhosis;
CH, chronic hepatitis; HS, healthy subjects. (TIF 1120 kb)
Additional file 2: Distribution of HCC patients according to BCLC
staging system. (TIF 62 kb)
Additional file 3: ROC curves and intensities of the differential ions
in the UPLC-MS 4-peak model by RT and m/z. ROC curves and
intensities of the differential ions in HCC (red boxes) and CH (green
boxes) for (A) RT 1.30_498.8315m/z; (B) RT 1.32_497.5731m/z; (C) RT
1.30_496.6721m/z; (D) RT 4.26_540.4255m/z. AUC, area under the curve;
HCC, hepatocellular carcinoma; LC, liver cirrhosis; CH, chronic hepatitis;
HS, healthy subjects. (TIF 4244 kb)
Additional file 4: ROC curves and intensities of the differential ions
by RT and m/z. ROC curves and intensities of the differential ions in HCC
(red boxes) and CH (green boxes) for (A) RT 3.40_773.5478n; (B) RT
4.23_851.6090m/z; (C) RT 3.59_770.5691m/z; (D) RT 3.45_822.5670m/z; (E)
RT 6.25_369.3538m/z; (F) RT 1.87_534.3902m/z; (G) RT 3.99_826.5920m/z.
AUC, area under the curve; HCC, hepatocellular carcinoma; LC, liver
cirrhosis; CH, chronic hepatitis; HS, healthy subjects. (TIF 7531 kb)
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